Abstract 420P
Background
KRAS mutations define a molecular subgroup of non-small cell lung cancer (NSCLC). KRAS G12C mutations can be targeted by small molecule inhibitors. Further investigation of cellular and molecular components of KRASm NSCLC is warranted to understand the disease mechanisms and guide precise treatment.
Methods
Tumor specimens of KRASm NSCLC were histologically evaluated, DNA and RNA were extracted. Comprehensive genomic and transcriptomic profiling were detected by Illumina TruSight Oncology 500 kit and TruSeq RNA Exome kit. Correlation analysis included demographic and clinical data as well.
Results
Among 162 cases of KRASm NSCLC, there were 141 males and 21 females, 140 adenocarcinoma and 8 squamous cell carcinoma, 2 sarcoid carcinoma, 1 large cell carcinoma and 1 NOS, 121 smokers and 41 non-smokers. Using next-generation sequencing (NGS), C>T transition signatures were found most often, followed by C>A, T>C, C>G, T>G, and T>A. KRAS mutations included 68 G12Cs, 33 G12Ds, 32 G12Vs, 9 G12As, 6 G13Ds, 6 Q61H/Ls and others. Major co-altered genes included TP53, LRP1B, FAT1, STK11, ARID1B, PTPRD, SPTA1, NOTCH3, NOTCH1, MGA, KEAP1, ZFHX3, etc. The genes co-alterations with KRAS were TP53 (59, 35.1%), followed by STK11 (27, 16.1%), STK11/TP53 (20, 11.9%), CDKN2A/TP53 (7, 4.2%), CDKN2A/STK11 (4, 3.4%) and CDKN2A/STK11/TP53 (3, 1.8%). Using MDACC's report, four groups were established: KL, KP, KC, and K-only. Correlation of genotypes with clinical outcome after adjuvant therapies will be analysed. Compared with adjacent tissues, KRASm cancer tissues had differentially expressed genes (DEGs) enriched in pathways of cytokine receptor interaction, primary immunodeficiency, intestinal immune network for IgA production, and etc. All KRAS tumors can be categorized into low and high inflamed groups by StromalScore, ImmuneScore and ESTIMATEScore methods.
Conclusions
Chinese KRAS mutant lung cancers are highly heterogeneous in terms of both KRAS mutations and co-altered genes and varied in inflammatory status in tumor microenvironment as well. Molecular and immune characteristics in KRASm NSCLC may influence the clinical outcome of adjuvant therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Natural Science Foundation of China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial
Presenter: Ying Jin
Session: Poster Display
Resources:
Abstract
498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study
Presenter: Thao Tu
Session: Poster Display
Resources:
Abstract
499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
Presenter: Daichi Fujimoto
Session: Poster Display
Resources:
Abstract
500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)
Presenter: Hidehito Horinouchi
Session: Poster Display
Resources:
Abstract
501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy
Presenter: Xin Wang
Session: Poster Display
Resources:
Abstract
502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
Presenter: Kentaro Tamura
Session: Poster Display
Resources:
Abstract
503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC
Presenter: TSUYOSHI HIRATA
Session: Poster Display
Resources:
Abstract
504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre
Presenter: Praveen Kumar Marimuthu
Session: Poster Display
Resources:
Abstract
505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Junjie Hu
Session: Poster Display
Resources:
Abstract
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract